Prognostic significance of stromal versican expression in human endometrial cancer

J. Kodama, Hasengaowa, T. Kusumoto, N. Seki, T. Matsuo, Y. Ojima, Keiichiro Nakamura, A. Hongo, Y. Hiramatsu

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in human endometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers. Patients and methods: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome. Results: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P <0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS. Conclusions: Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.

Original languageEnglish
Pages (from-to)269-274
Number of pages6
JournalAnnals of Oncology
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Versicans
Endometrial Neoplasms
Neoplasm Metastasis
Disease-Free Survival
Lymph Nodes
Neoplasms
Lymph
Blood Vessels

Keywords

  • Endometrial cancer
  • Prognosis
  • Tumor progression
  • Versican

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kodama, J., Hasengaowa, Kusumoto, T., Seki, N., Matsuo, T., Ojima, Y., ... Hiramatsu, Y. (2007). Prognostic significance of stromal versican expression in human endometrial cancer. Annals of Oncology, 18(2), 269-274. https://doi.org/10.1093/annonc/mdl370

Prognostic significance of stromal versican expression in human endometrial cancer. / Kodama, J.; Hasengaowa; Kusumoto, T.; Seki, N.; Matsuo, T.; Ojima, Y.; Nakamura, Keiichiro; Hongo, A.; Hiramatsu, Y.

In: Annals of Oncology, Vol. 18, No. 2, 02.2007, p. 269-274.

Research output: Contribution to journalArticle

Kodama, J, Hasengaowa, Kusumoto, T, Seki, N, Matsuo, T, Ojima, Y, Nakamura, K, Hongo, A & Hiramatsu, Y 2007, 'Prognostic significance of stromal versican expression in human endometrial cancer', Annals of Oncology, vol. 18, no. 2, pp. 269-274. https://doi.org/10.1093/annonc/mdl370
Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y et al. Prognostic significance of stromal versican expression in human endometrial cancer. Annals of Oncology. 2007 Feb;18(2):269-274. https://doi.org/10.1093/annonc/mdl370
Kodama, J. ; Hasengaowa ; Kusumoto, T. ; Seki, N. ; Matsuo, T. ; Ojima, Y. ; Nakamura, Keiichiro ; Hongo, A. ; Hiramatsu, Y. / Prognostic significance of stromal versican expression in human endometrial cancer. In: Annals of Oncology. 2007 ; Vol. 18, No. 2. pp. 269-274.
@article{89930e646d0e42d58ccc72be782d6c06,
title = "Prognostic significance of stromal versican expression in human endometrial cancer",
abstract = "Background: Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in human endometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers. Patients and methods: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome. Results: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P <0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS. Conclusions: Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.",
keywords = "Endometrial cancer, Prognosis, Tumor progression, Versican",
author = "J. Kodama and Hasengaowa and T. Kusumoto and N. Seki and T. Matsuo and Y. Ojima and Keiichiro Nakamura and A. Hongo and Y. Hiramatsu",
year = "2007",
month = "2",
doi = "10.1093/annonc/mdl370",
language = "English",
volume = "18",
pages = "269--274",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Prognostic significance of stromal versican expression in human endometrial cancer

AU - Kodama, J.

AU - Hasengaowa,

AU - Kusumoto, T.

AU - Seki, N.

AU - Matsuo, T.

AU - Ojima, Y.

AU - Nakamura, Keiichiro

AU - Hongo, A.

AU - Hiramatsu, Y.

PY - 2007/2

Y1 - 2007/2

N2 - Background: Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in human endometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers. Patients and methods: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome. Results: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P <0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS. Conclusions: Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.

AB - Background: Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in human endometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers. Patients and methods: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome. Results: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P <0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS. Conclusions: Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.

KW - Endometrial cancer

KW - Prognosis

KW - Tumor progression

KW - Versican

UR - http://www.scopus.com/inward/record.url?scp=33847281322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847281322&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl370

DO - 10.1093/annonc/mdl370

M3 - Article

VL - 18

SP - 269

EP - 274

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -